eprintid: 10130689 rev_number: 16 eprint_status: archive userid: 608 dir: disk0/10/13/06/89 datestamp: 2021-07-06 11:35:50 lastmod: 2022-09-09 08:57:13 status_changed: 2021-07-06 11:35:50 type: article metadata_visibility: show creators_name: Chopra, R creators_name: Preston, GC creators_name: Keenan, TDL creators_name: Mulholland, P creators_name: Patel, PJ creators_name: Balaskas, K creators_name: Hamilton, RD creators_name: Keane, PA title: Intravitreal injections: past trends and future projections within a UK tertiary hospital ispublished: pub subjects: GOSH subjects: MOOR divisions: UCL divisions: B02 divisions: C07 divisions: D08 note: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. abstract: Aims: To describe past trends and future projections for the number of intravitreal injections being administered at a large tertiary hospital in London, United Kingdom. Methods: Retrospective data from Moorfields Eye Hospital were collected using the electronic medical record system. Descriptive statistics were used to visualise overall trends. Time series forecasting was used to predict the number of injections that will be administered up to and including the year 2029. Results: The number of injections has increased nearly 11-fold from 2009 to 2019, with a total of 44,924 injections delivered in 2019. The majority of injections were given for the treatment of neovascular age-related macular degeneration. Aflibercept formed 87% of injections administered in 2019. The number of injections is predicted to continue to increase every year, with nearly 83,000 injections forecasted in the year 2029. Conclusion: The demand for intravitreal injections has increased substantially over the last decade and is predicted to further increase. Healthcare systems will need to adapt to accommodate the high demand. Other solutions may include longer-acting therapies to reduce the treatment burden. date: 2021-06-14 date_type: published official_url: https://doi.org/10.1038/s41433-021-01646-3 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1874900 doi: 10.1038/s41433-021-01646-3 lyricists_name: Balaskas, Konstantinos lyricists_name: Chopra, Reena lyricists_name: Keane, Pearse lyricists_id: KBALA95 lyricists_id: RCHOP17 lyricists_id: KPEAR28 actors_name: Chopra, Reena actors_id: RCHOP17 actors_role: owner full_text_status: public publication: Eye citation: Chopra, R; Preston, GC; Keenan, TDL; Mulholland, P; Patel, PJ; Balaskas, K; Hamilton, RD; Chopra, R; Preston, GC; Keenan, TDL; Mulholland, P; Patel, PJ; Balaskas, K; Hamilton, RD; Keane, PA; - view fewer <#> (2021) Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye 10.1038/s41433-021-01646-3 <https://doi.org/10.1038/s41433-021-01646-3>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10130689/1/s41433-021-01646-3.pdf